AREG
AREG (Amphiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Head and neck squamous cell carcinoma and Non-small-cell lung cancer.
Overview
Ligand of the EGF receptor/EGFR. Autocrine growth factor as well as a mitogen for a broad range of target cells including astrocytes, Schwann cells and fibroblasts.
CIViC holds 5 clinical evidence items and 0 assertions across 2 variants, naming Crizotinib, Cetuximab, Panitumumab and Docetaxel. Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.73, genetic association 0.00).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · AREG (Amphiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Head and neck squamous cell carcinoma and Non-small-cell lung cancer.
- 1 · What it is
AREG (Amphiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Head and neck squamous cell carcinoma and Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Ligand of the EGF receptor/EGFR. Autocrine growth factor as well as a mitogen for a broad range of target cells including astrocytes, Schwann cells and fibroblasts.
- 3 · How drugs use it
No product in this corpus aims at AREG yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:651 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15514 (protein name, function text, keywords and locations (REST API)); CIViC gene AREG (5 evidence items, 0 assertions, 2 variants; diseases: Lung Non-small Cell Carcinoma, Colorectal Cancer, Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000109321 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0))
Biology
Ligand of the EGF receptor/EGFR. Autocrine growth factor as well as a mitogen for a broad range of target cells including astrocytes, Schwann cells and fibroblasts. Location: Membrane (UniProt). Locus 4q13.3 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
- Head and neck squamous cell carcinoma: CIViC evidence names this disease
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; CIViC holds 5 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"AREG" OR ABSTRACT:"AREG" OR TITLE:"amphiregulin" OR ABSTRACT:"amphiregulin" OR TITLE:"Amphiregulin" OR ABSTRACT:"Amphiregulin" OR TITLE:"CRDGF" OR ABSTRACT:"CRDGF" OR TITLE:"AREGB" OR ABSTRACT:"AREGB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AREG, not a curated reading list.